Shopping Cart 0
Cart Subtotal
USD 0

Allergan Plc (AGN) - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology, women's health, urology and anti-infective therapeutic categories. The company sells its products to retailers, drug wholesalers and distributors, including national retail drug and food store chains, mail order retailers, hospitals, clinics, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. It has operations in several countries across the Americas, Europe, Asia-Pacific, the Middle East and Africa. Allergan is headquartered in Dublin, Ireland.

Allergan Plc (AGN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note : Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Allergan Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8

Allergan Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 9

Allergan Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10

Allergan Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 11

Allergan Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12

Allergan Plc, Medical Equipment, Deal Details 16

Asset Purchase 16

Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 16

Allergan Acquires Aline Hyaluronic Acid Thread Technology From Aline Aesthetics 17

LifeCell Acquires Adipose Tissue Injector From TauTona 18

Venture Financing 19

ForSight Vision5 Raises Additional USD4 Million Financingc 19

ForSight Vision5 Raises Additional USD6 Million in Financing 20

Colorescience Raises USD15 Million in Series B Venture Financing 21

ForSight Vision5 Raises USD 15 Million In Series C Financing 22

Oculeve Raises USD 17 Million In Venture Financing 23

AqueSys Raises USD 43.6 Million In Series D Financing 24

Colorescience Raises USD 10 Million In Series A Financing 26

ForSight Vision5 Raises USD 9 Million In Series B-1 Financing 27

Anterios Raises USD 8.5 Million In Venture Financing 28

Anterios Raises USD 4.7 Million In Venture Financing 29

Oculeve Raises USD 7.6 Million In Venture Financing 30

Topokine Therapeutics Raises Funds Through Venture Financing 31

Colorescience Raises USD 15 Million In Venture Financing 32

Regado Biosciences Raises USD 51 Million In Series E Financing 33

Oculeve Raises Additional USD 0.2 Million In Venture Financing 35

ForSight Vision5 Raises USD 8 Million In Venture Financing 36

Uteron Pharma Raises USD 10.4 Million In Venture Financing 37

AqueSys Raises USD 12 Million In Venture Financing 38

Uteron Pharma Raises USD 19 Million In Venture Financing 39

Private Equity 40

TPG Capital Acquires Aptalis Pharma from Actavis 40

Partnerships 41

Medicines360 Enters Into Licensing Agreement With Actavis For Intrauterine Device 41

Enzymatica To Enter Into Licensing Agreement With Actavis For ColdZyme Mouth Spray 42

T2 Biosystems Enters into Agreement with Allergan 43

Allergan Enters into Co-Development Agreement with SonarMD 44

Syneron Medical and Allergan Enter into Agreement 45

Galderma Enters into Agreement with ZELTIQ Aesthetics 46

Advance Medical Enters Into Co-Marketing Agreement With Zeltiq Aesthetics For CoolSculpting System 47

Equity Offering 48

Allergan Files Registration Statement for Public Offering of Securities 48

Anterios Postpones IPO for up to USD54.6 Million 50

Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 51

Actavis Raises USD4.18 Billion in Public Offering of Shares 53

Regado Biosciences Completes Public Offering Of Shares For USD 60 Million 55

Regado Biosciences Completes Private Placement Of Shares For USD 20 Million 56

Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For USD 43 Million 57

Zeltiq Aesthetics Files Registration Statement For Public Offering Of Securities For USD 75 Million 59

Forest Labs Plans Rights Offering Of Common Stock 60

Debt Offering 61

Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 61

Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 62

Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 63

Forest Lab Completes Private Placement Of Notes Due 2019 For USD 1.05 Billion 64

Forest Lab Completes Private Placement Of Notes Due 2021 For USD 750 Million 65

Forest Labs Completes Private Placement Of Notes Due 2021 For USD 1.2 Billion 66

Asset Transactions 67

Novadaq to Acquire Rights to SPY Elite System from LifeCell 67

Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 68

Acquisition 70

Allergan to Acquire Elastagen 70

Allergan to Sell 10% Stake in Teva Pharma 71

Adcock Ingram to Acquire Genop 72

Allergan Sales to Acquire Keller Medical 73

Allergan Acquires ZELTIQ Aesthetics for USD2.48 Billion 74

Allergan Acquires LifeCell from Acelity for USD2.9 Billion 76

Allergan Acquires Tobira Therapeutics in Tender Offer 78

Carl Icahn Acquires Stake in Allergan 80

Allergan Acquires Anterios 81

Allergan Acquires AqueSys 82

Allergan Acquires Northwood Medical 83

Allergan Acquires Oculeve 84

Actavis Acquires Allergan for USD70.5 Billion 85

Actavis Completes Acquisition of Forest Labs for USD28 Billion 87

Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For USD 2.9 Billion 89

Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To USD 9.1 Million 91

Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To USD 305 Million 92

SkinMedica Acquires Colorescience, Maker Of Skincare Products 94

Allergan Plc-Key Competitors 95

Allergan Plc-Key Employees 96

Allergan Plc-Locations And Subsidiaries 97

Head Office 97

Other Locations & Subsidiaries 97

Recent Developments 105

Financial Announcements 105

Jul 26, 2018: Allergan reports strong second quarter 2018 results including GAAP net revenues of USD 4.1 Billion 105

Apr 30, 2018: Allergan Reports 3% Increase in First Quarter 2018 GAAP Net Revenues to USD 3.7 Billion 108

Jan 08, 2018: Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference 111

Nov 01, 2017: Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to USD 4.03 Billion 112

Aug 03, 2017: Allergan Reports Continued Strong Execution in Second Quarter 2017 with 9% Increase in GAAP Net Revenues to USD 4.0 Billion 116

May 09, 2017: Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to USD 3.6 Billion 120

Feb 08, 2017: Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to USD 3.9 Billion in Fourth Quarter 2016 124

Corporate Communications 128

Aug 08, 2018: Allergan appoints neurobiology expert Michael E Greenberg PhD to its Board of Directors as part of active board refreshment process 128

Jun 14, 2018: Allergan Continues Active Board Refreshment Process 129

May 03, 2018: John Davidson Elected to Allergan Board of Directors 130

Feb 05, 2018: Allergan Appoints Matthew M. Walsh As Executive Vice President and Chief Financial Officer 131

Dec 18, 2017: Allergan Announces Promotion of Wayne Swanton to Executive Vice President, Global Operations 132

Sep 11, 2017: The Allergan Foundation to Donate USD 150,000 to Support Hurricane Irma Relief Efforts 133

Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 134

Apr 10, 2017: Allergan Receives 2017 ENERGY STAR Partner of the Year-Sustained Excellence Award from U.S. Environmental Protection Agency 135

Apr 06, 2017: Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategy 136

Feb 27, 2017: Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan 137

Product News 138

Nov 08, 2017: Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans 138

Oct 11, 2017: Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference 139

Oct 05, 2017: Allergan Presents Data From Seventeen Abstracts At The 2017 American Society For Dermatologic Surgery Meeting In Chicago 140

May 04, 2017: Allergan to Present New Data at the 2017 American College of Obstetricians and Gynecologists (ACOG) Clinical and Scientific Meeting in San Diego 142

Jan 05, 2017: Allergan to Present at Goldman Sachs Healthcare CEOs Unscripted Conference and Provides Preliminary Comments on 2017 Outlook 143

Other Significant Developments 144

Jun 28, 2018: Allergan Eases Manual Data Entry and Contract Management Pains with Pramatas Billing Accuracy Solution 144

Sep 25, 2017: New Study Showcases Economic Impact of Allergan Operations on French Economy 145

Sep 14, 2017: Industry Leaders Allergan and Sientra Invest in The American Society for Aesthetic Plastic Surgery for Breast Implant Research 146

Sep 12, 2017: Allergan Launches New Brilliant Distinctions Patient Loyalty Program 147

Appendix 148

Methodology 148

About GlobalData 148

Contact Us 148

Disclaimer 148


List Of Figure

List of Figures

Allergan Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Allergan Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Allergan Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Allergan Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Allergan Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8

Allergan Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 9

Allergan Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10

Allergan Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 11


List Of Table

List of Tables

Allergan Plc, Medical Equipment, Key Facts, 2017 2

Allergan Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Allergan Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8

Allergan Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 9

Allergan Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10

Allergan Plc, Deals By Market, 2012 to YTD 2018 11

Allergan Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12

Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 16

Allergan Acquires Aline Hyaluronic Acid Thread Technology From Aline Aesthetics 17

LifeCell Acquires Adipose Tissue Injector From TauTona 18

ForSight Vision5 Raises Additional USD4 Million Financingc 19

ForSight Vision5 Raises Additional USD6 Million in Financing 20

Colorescience Raises USD15 Million in Series B Venture Financing 21

ForSight Vision5 Raises USD 15 Million In Series C Financing 22

Oculeve Raises USD 17 Million In Venture Financing 23

AqueSys Raises USD 43.6 Million In Series D Financing 24

Colorescience Raises USD 10 Million In Series A Financing 26

ForSight Vision5 Raises USD 9 Million In Series B-1 Financing 27

Anterios Raises USD 8.5 Million In Venture Financing 28

Anterios Raises USD 4.7 Million In Venture Financing 29

Oculeve Raises USD 7.6 Million In Venture Financing 30

Topokine Therapeutics Raises Funds Through Venture Financing 31

Colorescience Raises USD 15 Million In Venture Financing 32

Regado Biosciences Raises USD 51 Million In Series E Financing 33

Oculeve Raises Additional USD 0.2 Million In Venture Financing 35

ForSight Vision5 Raises USD 8 Million In Venture Financing 36

Uteron Pharma Raises USD 10.4 Million In Venture Financing 37

AqueSys Raises USD 12 Million In Venture Financing 38

Uteron Pharma Raises USD 19 Million In Venture Financing 39

TPG Capital Acquires Aptalis Pharma from Actavis 40

Medicines360 Enters Into Licensing Agreement With Actavis For Intrauterine Device 41

Enzymatica To Enter Into Licensing Agreement With Actavis For ColdZyme Mouth Spray 42

T2 Biosystems Enters into Agreement with Allergan 43

Allergan Enters into Co-Development Agreement with SonarMD 44

Syneron Medical and Allergan Enter into Agreement 45

Galderma Enters into Agreement with ZELTIQ Aesthetics 46

Advance Medical Enters Into Co-Marketing Agreement With Zeltiq Aesthetics For CoolSculpting System 47

Allergan Files Registration Statement for Public Offering of Securities 48

Anterios Postpones IPO for up to USD54.6 Million 50

Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 51

Actavis Raises USD4.18 Billion in Public Offering of Shares 53

Regado Biosciences Completes Public Offering Of Shares For USD 60 Million 55

Regado Biosciences Completes Private Placement Of Shares For USD 20 Million 56

Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For USD 43 Million 57

Zeltiq Aesthetics Files Registration Statement For Public Offering Of Securities For USD 75 Million 59

Forest Labs Plans Rights Offering Of Common Stock 60

Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 61

Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 62

Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 63

Forest Lab Completes Private Placement Of Notes Due 2019 For USD 1.05 Billion 64

Forest Lab Completes Private Placement Of Notes Due 2021 For USD 750 Million 65

Forest Labs Completes Private Placement Of Notes Due 2021 For USD 1.2 Billion 66

Novadaq to Acquire Rights to SPY Elite System from LifeCell 67

Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 68

Allergan to Acquire Elastagen 70

Allergan to Sell 10% Stake in Teva Pharma 71

Adcock Ingram to Acquire Genop 72

Allergan Sales to Acquire Keller Medical 73

Allergan Acquires ZELTIQ Aesthetics for USD2.48 Billion 74

Allergan Acquires LifeCell from Acelity for USD2.9 Billion 76

Allergan Acquires Tobira Therapeutics in Tender Offer 78

Carl Icahn Acquires Stake in Allergan 80

Allergan Acquires Anterios 81

Allergan Acquires AqueSys 82

Allergan Acquires Northwood Medical 83

Allergan Acquires Oculeve 84

Actavis Acquires Allergan for USD70.5 Billion 85

Actavis Completes Acquisition of Forest Labs for USD28 Billion 87

Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For USD 2.9 Billion 89

Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To USD 9.1 Million 91

Watson Pharma Acquires Uteron Pharma, Women's Health Company, For Up To USD 305 Million 92

SkinMedica Acquires Colorescience, Maker Of Skincare Products 94

Allergan Plc, Key Competitors 95

Allergan Plc, Key Employees 96

Allergan Plc, Other Locations 97

Allergan Plc, Subsidiaries 97

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Allergan Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.